TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04185103

Intervention type: DRUG
Intervention: Sacubitril-Valsartan
Description: After signing the Informed Consent, in the shortest possible time, the study investigator will carry out an ergometric test for the T-wave alternans (TWA) while still taking the basal medication. The patient will also sign the prototype Informed Consent for carrying out a stress test on a treadmill. It will also be carried out a basal life quality questionnaire, an analytical determination and a colour doppler echocardiography.
Study: NCT02554019

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BT063
Description: Repeated IV infusions over 12 weeks (at weeks 0, 1, 2, 4, 6, 8, 10, 12)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Repeated IV infusions over 12 weeks (at weeks 0, 1, 2, 4, 6, 8, 10, 12)
Study: NCT02205203

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mayo Clinic Anxiety Coach
Description: Mayo Clinic Anxiety Coach is a smartphone application based on cognitive-behavioral treatment for anxiety disorders (i.e., exposure-based therapy) that can be used as 1) a stand-alone treatment requiring minimal provider contact, and 2) an augmentation of face-to-face treatment that increases clinician fidelity and patient adherence to evidence-based treatment. The design of Anxiety Coach is based on evidence and theory suggesting that information and communication technologies (ICTs) are well-suited for encouraging behavior change through 1) scheduled reminders to engage in therapeutic exercises, 2) point of performance support, 3) individually tailored information, 4) real-time symptom assessment, and 5) readily accessible asynchronous communication.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: In the TAU condition therapists provide treatment consistent with their orientation and clinical judgment. Previous research suggests that TAU will include supportive therapy, relaxation, and cognitive restructuring. The format of treatment will be 6 to 12, 50-minute, face-to-face therapy sessions in the therapist's office, with flexibility to leave the office (e.g., for exposure).
Study: NCT02828553

Intervention type: OTHER
Intervention: Aggressive planned ambulation with a mobility aide
Description: A trained mobility aide will provide aggressive ambulation at least 3X per day for all patients on the heart failure unit
Study: NCT01513538

Intervention type: DEVICE
Intervention: TherapyGuide
Description: Use of TherapyGuide function to help programming the device
Study: NCT01785160

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: low dose oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: low dose oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faldaprevir
Description: medium dose oral administration
Study: NCT01901575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Patients with established PVC's , sedated with remifentanil IVPCA per study protocol
Study: NCT01908023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: One hour, twice a week, for 5 weeks: warming-up with aerobic exercises, endurance exercises, strength exercises for large muscle groups, body awareness, range-of- motion exercises for the shoulders and stretching and relaxation
Study: NCT00779480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-2449
Description: KW-2449 50 mg capsules administered 3 or 4 times per day for 21-day cycles up to 6 cycles
Study: NCT01021956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAKEL
Description: Open-label,safety and exploratory efficacy study in subjects with active CNV followed for 12 weeks.During first stage(dose escalating stage) subjects assigned to group 1 to 4 will receive a single treatment of VTP at one of three light levels and one of two Drug Light Interval (DLI).Second stage(dose confirmation)will be only initiated at a dose level in which an effect has been seen at week 1 and there is a maximum of one Dose Limiting Toxicity (DLT) out of three subject at week 5.
Study: NCT04182373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithrombin gamma
Description: Intravenous infusion, once a day, 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: physiological saline
Description: Intravenous infusion, once a day, 7 days
Study: NCT01378507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: endoscopic submucosal dissection
Description: ESD was carried out by using a single-channel upper gastrointestinal endoscope with a water-jet system (Q260J; Olympus Optical Co, Tokyo, Japan) and a high-frequency generator with an automatically controlled system (ENDOCUT mode) (Erbotom ICC 200; ERBE Elektromedizin GmbH, Tübingen, Germany). The transparent attachment was fitted on the tip of the endoscope mainly to obtain a constant endoscopic view and to create tension on the connective tissue for the submucosal dissection.
Study: NCT05578859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 510
Description: Single oral dose of AMG510.
Study: NCT01239342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study: NCT02302508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel, Prasugrel, Ticagrelor
Description: PK and PD parameters will be compared between groups and comparison will be performed between antiplatelet agents

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel, Prasugrel, Ticagrelor
Description: PK and PD parameters will be compared between groups and comparison will be performed between antiplatelet agents

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel, Prasugrel, Ticagrelor
Description: PK and PD parameters will be compared between groups and comparison will be performed between antiplatelet agents

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel, Prasugrel, Ticagrelor
Description: PK and PD parameters will be compared between groups and comparison will be performed between antiplatelet agents
Study: NCT01305642

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Individualized fortification of breast milk
Description: Lactose, fat and protein content will be measured prior to breast milk fortification.~Subsequently, breast milk for preterm infants will individually fortified adjusted by using data from milk analysis.
Study: NCT00798850

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty (PTA)
Description: PTA will be performed by a consultant interventional radiologist with no deviation from the standard protocol at Hull \& East Yorshire Yospitals NHS Trust.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Exercise Programme (SEP)
Description: SEP: Conducted 3 times per week for 12 weeks.The session will be supervised by a physiotherapist and conducted in the cardiac gym.~Each session begins with gentle warming up exercises followed by an exercise circuit of 6 stations(2 minutes each).~1. Station 1-Step-ups(20-cm high step,alternating leg after 10 step-ups)~2. Station 2-Exercise bicycles~3. Station 3-Knee extensions with weights(2kg beanbag)~4. Station 4-Heel raises~5. Station 5-Knee bends(Alternating legs after 10 bends)~6. Station 6-Rest station(2Kg Biceps curls) Gentle walk for 2minutes in between the stations to recover.For first 6weeks patients complete one full circuit, followed by on extra station/week, thus by 12weeks patients will complete 2 full circuits.Finally patients perform a series of gentle stretching and cooling down exercises.~This exercise programme was designed to comply with suggested guidelines based on a meta-analysis assessing the effectiveness of SEP for claudicants.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined Treatment
Description: PTA will be performed according to routine protocol followed by enrollment of patient in SEP. SEP will commence in the week following PTA.
Study: NCT02151955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual
Description: 10 to 15 Individual parent child therapeutic intervention focusing on the quality of the parent child relationships using attachment theory and parent infant psychotherapy
Study: NCT01848288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CENTURION® Vision System (CVS)
Description: Phacoemulsification aspiration platform, with configuration consisting of Centurion® Vision System Phaco Emulsifier Aspirator, 45° Balanced ultrasonic tip, and INTREPID Ultra Infusion Sleeve, for use during routine cataract extraction by phacoemulsification with intraocular lens implantation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CENTURION® Vision System (CVS)
Description: Phacoemulsification aspiration platform, with configuration consisting of Centurion® Vision System Phaco Emulsifier Aspirator, 45° Balanced ultrasonic tip, and INTREPID Ultra Infusion Sleeve, for use during routine cataract extraction by phacoemulsification with intraocular lens implantation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INFINITI® Vision System (IVS)
Description: Phacoemulsification aspiration platform, with configuration consisting of Infiniti® Vision System Phaco Emulsifier Aspirator, 45° Mini Flared Kelman tip, and Ultra Infusion Sleeve, for use during routine cataract extraction by phacoemulsification with intraocular lens implantation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: INFINITI® Vision System (IVS)
Description: Phacoemulsification aspiration platform, with configuration consisting of Infiniti® Vision System Phaco Emulsifier Aspirator, 45° Mini Flared Kelman tip, and Ultra Infusion Sleeve, for use during routine cataract extraction by phacoemulsification with intraocular lens implantation.
Study: NCT02947672

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intraperitoneal Dexamesathone
Study: NCT00079404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV
Study: NCT03066128

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Point-of-care viral load testing
Description: Point-of-care viral load testing will be performed while the participant is in the clinic to ensure that participants receive the viral load results on the same day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lab-based viral load testing
Description: Viral load testing will be lab based and follow standard of care procedures
Study: NCT00733148

Intervention type: DRUG
Intervention: dosing of insulin
Description: Dosing od insulin is calculated by a computer based algorithm

Intervention type: DRUG
Intervention: dosing of insulin
Description: Dosing od insulin is calculated by a computer based algorithm
Study: NCT02289430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crestor+Ezetrol
Description: rosuvastatin+ezetimibe

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetrol
Description: ezetimibe

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crestor
Description: rosuvastatin
Study: NCT03156920

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan
Description: Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Study: NCT02722538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200
Description: TAR-200 is a passive, nonresorbable gemcitabine-releasing intravesical drug delivery system, regulated as a drug, whose primary mode of action is the controlled release of gemcitabine into the bladder over a 7-day period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200
Description: TAR-200 is a passive, nonresorbable gemcitabine-releasing intravesical drug delivery system, regulated as a drug, whose primary mode of action is the controlled release of gemcitabine into the bladder over a 7-day period.
Study: NCT02590120

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enteral nutrition

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enteral nutrition
Study: NCT03023020

Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin
Description: Dosing per current guidelines and local practice

Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin
Description: Dosing per current guidelines and local practice

Intervention type: DRUG
Group type: OTHER
Intervention: P2Y12 inhibitor
Description: Dosing per current guidelines and local practice

Intervention type: DRUG
Group type: OTHER
Intervention: P2Y12 inhibitor
Description: Dosing per current guidelines and local practice
Study: NCT00794599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg (Clarinex)
Description: Clarinex 5 mg daily x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg (Clarinex)
Description: Clarinex 5 mg daily x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine (Zyrtec)
Description: Zyrtec 10 mg daily x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine (Zyrtec)
Description: Zyrtec 10 mg daily x 7 days
Study: NCT00880399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orvepitant
Description: Neurokinin-1 (NK-1) antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orvepitant
Description: Neurokinin-1 (NK-1) antagonist

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: inactive placebo to match orvepitant 30 and 60 mg dosage forms
Study: NCT01160757

Intervention type: DEVICE
Group type: OTHER
Intervention: ultrasound
Description: ultrasound exposure on acute acne lesions
Study: NCT01922817

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saxagliptin
Description: 5mg saxagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin
Description: 5mg saxagliptin
Study: NCT03113240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamin
Description: Enteral Glutamine 0.3g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin mixed with water given via NG tube q 4 hours.
Study: NCT01399554

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy plus Contingency Management
Description: A combination of two motivational enhancement therapy (MET) sessions focused on increasing exercise spaced two months apart and four months of weekly contingency management (CM) for adhering to specific exercise activities. MET is a client-centered, directive method of enhancing intrinsic motivation to change by exploring and resolving ambivalence, and CM is a behavioral treatment offering individuals tangible reinforcers such as prizes for completion of specific target behaviors.
Study: NCT04096027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline Pill
Description: 0.5 mg cabergoline pill taken orally
Study: NCT01980537

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional wire navigation
Study: NCT04114149

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS (transcutaneous electrical nerve stimulation)
Description: TENS as first line of treatment. If insufficient pain relief, i.e. postoperative pain intensity according to NRS (numeric rating scale) ≥ 3 after two treatment sessions à 1 minute, the patient receives conventional treatment with iv opioids.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iv opioid
Description: Conventional treatment with iv opioid if postoperative pain intensity according to NRS (numeric rating scale) ≥ 3.
Study: NCT01427998

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: olive leaf extract
Description: olive leaf extract, 1 pill daily, 500 mg, for a duration of 14 wks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT04474769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention for preceptors
Study: NCT03443076

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA + DHA in SMEDS Formulation
Description: A single dose of 500 mg EPA + DHA administered in a self-micro-emulsifying delivery system (SMEDS) formulation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lovaza (active comparator; already FDA approved)
Description: A single dose of 840 mg EPA + DHA administered as Lovaza. This intervention was used as an active comparator in this study. Lovaza was already FDA-approved when the study was conducted.
Study: NCT00139776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: 24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind celecoxib 200 mg daily.~Placebo used as flare medication when directed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: 24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind placebo daily.~Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed.
Study: NCT02064530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 21 ml 0.5 %bupivacaine is applied interfasially

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied interfasially

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: serum physiologic
Description: 21 ml serum physiologic is applied interfasially
Study: NCT03168776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BuMA Supreme DES
Description: Implant BuMA Supreme stent only

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience or Promus DES
Description: Implant XIENCE family or Promus family only
Study: NCT02755246

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyamine supplementation
Description: 3 months of polyamine supplementation (3 capsules/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementation
Description: 3 months of placebo intake (3 capsules/day)
Study: NCT00873483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol/Gestodene (BAY86-5016)
Description: 0.55 mg ethinyl estradiol \& 2.1 mg gestodene, 21 days for 3 cycles
Study: NCT00616759

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: electroconvulsive therapy
Description: electroconvulsive therapy as usual
Study: NCT02422420

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Description: Use of financial incentives to promote health behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Description: Use of financial incentives to promote health behaviors.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Financial Incentives
Description: Use of financial incentives to promote health behaviors.
Study: NCT00226109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spironolactone
Description: 100 mg once daily. Can be reduced to 50 mg a day still maintaining the doubled-blinded status
Study: NCT02286414

Intervention type: DRUG
Intervention: Direct oral antocoagulant: dabigatran, rivaroxaban, apixaban
Description: Exposure to direct oral antocoagulants : dabigatran, rivaroxaban, apixaban

Intervention type: DRUG
Intervention: Vitamin K antagonist: warfarin, fluindione, acenocoumarol
Description: Exposure to vitamin K antagonist
Study: NCT00111800

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEN 2.5 mg
Description: DEN 2.5 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEN 7.5 mg
Description: DEN 7.5 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEN 15 mg
Description: DEN 15 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEN 30 mg
Description: DEN 30 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEN 45 mg
Description: DEN 45 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
Study: NCT00146315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised exercise on a stationary bicycle, 3-5 days a week
Description: Supervised exercise on a stationary bicycle, 3-5 days a week, plus a secondary prevention program for coronary heart disease

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Secondary prevention program for coronary heart disease
Description: Secondary prevention program for coronary heart disease
Study: NCT00889148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 600mg gabapentin given 2 hrs preoperatively and 200mg three times a day after surgery for 3 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Half the patients will be randomized to placebo
Study: NCT04082403

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Training on Suction Assisted Laryngoscopy and Airway Decontamination
Description: Education on Suction Assisted Laryngoscopy and Airway Decontamination, via 30 minute teaching session, followed by practical demonstration of techniques.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No Training on Suction Assisted Laryngoscopy and Airway Decontamination Provided
Description: No Training on Suction Assisted Laryngoscopy and Airway Decontamination provided to trainees